Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.001
Neutral
RSI(14)
35.053
Neutral
STOCH(KDJ)(9,3,3)
32.339
Neutral
ATR(14)
0.029
High Vlolatility
CCI(14)
-71.504
Neutral
Williams %R
72.750
Sell
TRIX(12,20)
-1.191
Sell
StochRSI(14)
39.035
Sell
Search
Mereo BioPharma Group PLC
MREOAdd to Watchlist
0.241USD
-0.004-1.83%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
38.55MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Mereo BioPharma Group PLC
Currency: USD Updated: 2026-05-15Key Insights
Mereo BioPharma Group PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 126 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.75.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mereo BioPharma Group PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Mereo BioPharma Group PLC Highlights
StrengthsRisks
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Growing
The company is in a growing phase, with the latest annual income totaling USD 500.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 500.00K.
Overvalued
The company’s latest PE is -1.09, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 69.97M shares, decreasing 49.34% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 194.37K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
1.750
Target Price
+611.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Mereo BioPharma Group PLC is 7.58, ranking 74 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.45
Operational Efficiency
2.86
Growth Potential
10.00
Shareholder Returns
7.58
Mereo BioPharma Group PLC's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Mereo BioPharma Group PLC is 7.17, ranking 149 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.09, which is -16.83% below the recent high of -0.90 and -8360.95% above the recent low of -91.85.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 126/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Mereo BioPharma Group PLC is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 9.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
1.750
Target Price
+611.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Mereo BioPharma Group PLC
MREO
8
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Mereo BioPharma Group PLC is 5.95, ranking 295 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.31 and the support level at 0.19, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.247
Sell
MA10
0.253
Sell
MA20
0.274
Sell
MA50
0.318
Sell
MA100
0.458
Sell
MA200
1.160
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Mereo BioPharma Group PLC is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 43.84%, representing a quarter-over-quarter decrease of 38.82%. The largest institutional shareholder is James Simons, holding a total of 48.40K shares, representing 0.03% of shares outstanding, with 96.43% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Mereo BioPharma Group PLC is 1.30, ranking 314 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.17. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.22
VaR
+7.26%
240-Day Maximum Drawdown
+91.93%
240-Day Volatility
+253.83%
Return
Best Daily Return
60 days
+10.42%
120 days
+29.82%
5 years
+62.50%
Worst Daily Return
60 days
-14.89%
120 days
-87.65%
5 years
-87.65%
Sharpe Ratio
60 days
-3.35
120 days
-0.63
5 years
+0.18
Risk Assessment
Maximum Drawdown
240 days
+91.93%
3 years
+95.13%
5 years
+95.13%
Return-to-Drawdown Ratio
240 days
-0.98
3 years
-0.28
5 years
-0.19
Skewness
240 days
-4.59
3 years
-4.21
5 years
-1.12
Volatility
Realised Volatility
240 days
+253.83%
5 years
+145.69%
Standardised True Range
240 days
+42.98%
5 years
+60.85%
Downside Risk-Adjusted Return
120 days
-62.05%
240 days
-62.05%
Maximum Daily Upside Volatility
60 days
+48.80%
Maximum Daily Downside Volatility
60 days
+47.08%
Liquidity
Average Turnover Rate
60 days
+0.21%
120 days
+1.00%
5 years
--
Turnover Deviation
20 days
-46.03%
60 days
-45.19%
120 days
+162.10%
Peer Comparison
Biotechnology & Medical Research
Mereo BioPharma Group PLC
MREO
6.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
